



**BlueCross  
BlueShield**

**Federal Employee Program. PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: 1-877-378-4727

Patient Information (required)				Provider Information (required)		
Date:				Provider Name:		
Patient Name:				Specialty:		NPI:
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female			Office Phone:		Office Fax:
Street Address:				Office Street Address:		
City:	State:	Zip:		City:	State:	Zip:
Patient ID:	R <input type="text"/>			Physician Signature:		
<b>PHYSICIAN COMPLETES</b>						

**Tukysa (tucatinib)**

**NOTE:** Form must be completed in its **entirety** for processing

<b>Please select strength:</b>	<input type="checkbox"/> 50mg qty _____ per 90 days	<input type="checkbox"/> 150mg qty _____ per 90 days
--------------------------------	---	--

**\*\*Check [www.fepblue.org/formulary](http://www.fepblue.org/formulary) to confirm which medication is part of the patient's benefit**

Is this request for brand or generic? ☐ Brand ☐ Generic

1. Has the patient been on Tukysa continuously for the last **6 months, excluding samples**? *Please select answer below:*

☐ **NO** – this is **INITIATION** of therapy, please answer the following questions:

a. What is the patient's diagnosis?

☐ Advanced unresectable or metastatic breast cancer

i. Has the patient previously received one or more anti-HER2-based regimens? ☐ Yes ☐ No

ii. Will Tukysa be used in combination with trastuzumab and capecitabine? ☐ Yes ☐ No

☐ Unresectable or metastatic colorectal cancer

i. Does the patient have RAS wild-type unresectable or metastatic colorectal cancer, as determined by an FDA-approved test? ☐ Yes ☐ No

ii. Has the cancer progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy? ☐ Yes ☐ No

iii. Will Tukysa be used in combination with trastuzumab? ☐ Yes ☐ No

☐ Other diagnosis (*please specify*): \_\_\_\_\_

b. Is the patient's cancer human epidermal growth factor receptor 2 (HER2)-positive? ☐ Yes ☐ No

c. Does the prescriber agree to obtain the patient's baseline AST, ALT, and bilirubin levels? ☐ Yes ☐ No

☐ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following questions:

a. What is the patient's diagnosis?

☐ Advanced unresectable or metastatic breast cancer

i. Will Tukysa be used in combination with trastuzumab and capecitabine? ☐ Yes ☐ No

☐ Unresectable or metastatic colorectal cancer

i. Will Tukysa be used in combination with trastuzumab? ☐ Yes ☐ No

☐ Other diagnosis (*please specify*): \_\_\_\_\_

b. Has the patient experienced disease progression or unacceptable toxicity while on Tukysa? ☐ Yes ☐ No

2. Does the prescriber agree to monitor the patient's AST, ALT, and bilirubin levels during treatment? ☐ Yes ☐ No

3. **FEMALE Patient:** Is the patient of reproductive potential? ☐ Yes\* ☐ No

*\*If YES, will the patient be advised to use effective contraception during treatment with Tukysa and for one week after the last dose?* ☐ Yes ☐ No

4. **MALE Patient:** Does the patient have a female partner of reproductive potential? ☐ Yes\* ☐ No

*\*If YES, will the patient be advised to use effective contraception during treatment with Tukysa and for one week after the last dose?* ☐ Yes ☐ No



**BlueCross  
BlueShield**

Federal Employee Program.

**TUKYSA**

**PRIOR APPROVAL REQUEST**

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn. Clinical Services  
Fax: **1-877-378-4727**

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

<p><b>Electronically Online (ePA)</b></p> <p><b>Results in 2-3 minutes FASTEST AND EASIEST</b></p>	<p>Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls.</p> <p>Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA</b>.</p>
<p><b>Phone</b></p> <p><b>(4-5 minutes for response)</b></p>	<p>The FEP Clinical Call Center can be reached at <b>(877)-727-3784</b> between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service.</p> <p>The process over the phone takes on average between 4 and 5 minutes.</p>
<p><b>Fax</b></p> <p><b>(3-5 days for response)</b></p>	<p>Fax the attached form to <b>(877)-378-4727</b>. Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed.</p> <p><b><u>Please only fax the completed form once as duplicate submissions may delay processing times.</u></b></p>

faster...  
easier...  
better...

Introducing ePA! Online Prior Authorizations in minutes through **Caremark.com/ePA**. Sign up today!

**CVS/caremark** 